Basophil Activation Test With Aspergillus Molecules: The Case for ABPA

Moïse Michel¹,², Youssouf Sereme², Farid Mankouri³, Marion Gouitaa³, Clarisse Gautier³, Jean-Louis Mège²,³, Carole Cassagne³,⁴, Stéphane Ranque³,⁴, Martine Reynaud-Gaubert²,³ and Joana Vitte²,⁵

¹Laboratoire d’Immunologie, CHU Carémeau Nîmes, Nîmes, France, ²Aix-Marseille Université, APHM, IRD, MEPhI, Marseille, France, ³Assistance Publique–Hôpitaux de Marseille, Marseille, France, ⁴Aix-Marseille Université, APHM, IRD, VITROME, Marseille, France, ⁵IDESP, INSERM UA11, Université de Montpellier, Montpellier, France

Background: Allergic bronchopulmonary aspergillosis (ABPA) is an underestimated allergic disease due to Aspergillus fumigatus (AF). The main diagnostic criteria for ABPA rely on the evaluation of immunoglobulin (Ig) E and IgG responses to AF extracts, although these cannot discriminate AF-sensitization from ABPA.

Objectives: To evaluate the performance of cellular functional assays with extract and molecular AF allergens in ABPA.

Methods: A prospective cohort of 67 patients (6 ABPA) was investigated with basophil activation test (BAT) with AF extract. Twelve patients were further investigated for BAT responses to molecular AF components: Asp f 1, Asp f 2, Asp f 3, Asp f 4, and Asp f 6.

Results: BAT with AF extract with an optimized cutoff displayed 100% sensitivity and 77.6% specificity for ABPA diagnosis. Among patients with positive BAT to AF, BAT with Asp f 4 was significantly higher in ABPA patients at 10 ng/mL (mean basophil stimulation index 10.56 in ABPA vs. 1.24 in non-ABPA patients, p = 0.0002).

Conclusion: BAT with AF is a promising diagnostic biomarker in the context of suspected ABPA, which can be further improved with AF molecular allergens, especially Asp f 4.

Keywords: allergic bronchopulmonary aspergillosis (ABPA), basophil activating test (BAT), Aspergillus fumigatus, aspergillus molecular allergens, ex vivo technique

INTRODUCTION

Allergic bronchopulmonary aspergillosis (ABPA) is an underestimated allergic disease due to the ubiquitous mold Aspergillus fumigatus (AF). ABPA occurs mainly in patients with a chronic pulmonary disease, such as cystic fibrosis (CF), asthma or chronic obstructive pulmonary disease (COPD) (1). Its prevalence reaches 10 and 2% in CF and asthma patients, respectively (2, 3). Up to now, the reason why some AF-sensitized people stay free of subsequent AF-related disease whereas others develop ABPA with irreversible pulmonary lesions remains unknown. The main diagnostic criteria for ABPA, first established in 1977 (4), rely on the evaluation of humoral IgE and IgG responses to AF extracts, which cannot discriminate ABPA from AF-sensitization. Several new diagnostic tools have been evaluated, but none has overcome this limitation (2, 5, 6). More recently,
serum immunoglobulin (Ig) E responses to AF molecular components have been proposed, and the combination of specific AF molecular components showed promise for ABPA diagnosis (7–9). Meanwhile, diagnostic criteria based on the evaluation of functional cellular responses against allergens are increasingly cited in international guidelines (10, 11). Performance of the basophil activation test (BAT) with AF extract has been explored (12–16), but its relevance for ABPA diagnosis needs further evaluation. To our best knowledge, AF-induced basophil reactivity has not been deciphered at a molecular level, despite promising results of profiling IgE responses to such molecules. We report here the performance of BAT with AF extract and AF molecular allergens vs. usual diagnostic criteria of ABPA in a prospective cohort.

PATIENTS AND METHODS

Patient Cohort

We assessed adult patients (n = 67) followed at the CF reference care center and at the pulmonology department (Assistance Publique—Hôpitaux de Marseille, France) between January and September 2019. Patients were categorized as ABPA, AF-sensitized (AF-S), or control patients. These categories were defined as follows: ABPA met all the ISHAM criteria (2); AF-S displayed specific IgE (sIgE) to AF (0.1 kUA/L or greater) without fulfilling the ISHAM criteria for ABPA; and patients who were categorized in none of the two previous groups were considered as controls. According to ISHAM criteria, ABPA is made in patients with a lung predisposing condition who display AF sensitization and elevated total IgE levels and at least 2 of the following 3 criteria: (1) detection of AF specific IgG, (2) radiographic abnormalities, (3) total eosinophil count above 500 cells/µL.

Functional Cytometric Tests

The design of functional cellular assays is illustrated in Figure 1. BAT was firstly performed with AF extract (Bühlmann Laboratories®, Schönenbuch, Switzerland) with the Flow2CAST method (Bühlmann Laboratories®), using CCR3 (CD193) and CD63 as basophil identification and activation markers, following the manufacturer’s instructions (17). Upon allergen contact, sensitized basophils degranulate and express CD63 as a cell surface activation marker, measurable by flow cytometry. For in vitro diagnosis, allergen-induced basophil activation is defined as a proportion of CD63+ basophils at least twice higher with the culprit allergen than with the reaction buffer. Positive controls were anti-FcεRI and the bacterial peptide fMLP. Fresh whole blood was incubated with AF extract or controls and staining antibodies for 30 mins at 37°C. After red cell lysis and washes, basophil responses were analyzed by flow cytometry. The proportion of CD63+ unstimulated basophils was lower than 5% in all patients, and no non-responder (anti-FcεRI-induced CD63 expression of 10% or less) was found in this cohort.

Samples with a positive BAT response to AF extract were subsequently assayed by BAT using each of the five following molecular AF: Asp f 1, Asp f 2, Asp f 3, Asp f 4 and Asp f 6 (a gift from Dr Jonas Lidholm, Thermo Fisher Scientific, R&D, Uppsala, Sweden). These molecular AF are the same used in the ImmunoCAP platform. Five concentrations of molecular components from 100 to 0.01 ng/mL by 10-fold dilution were used for each patient.

Flow cytometry was performed with a FACS Canto II platform (Becton Dickinson, Le Pont de Clai, France). At least 200 basophils per sample were acquired for BAT. Data were analyzed using FACS Diva software (TreeStar, Ashland, OR).

Clinical and Laboratory Data

White blood cell count (Sysmex, Villepinte, France) and serum total IgE and specific IgE (sIgE) and IgG (sIgG) to AF extract and molecular components Asp f 1, Asp f 2, Asp f 3, Asp f 4 and Asp f 6 (ImmunoCAP, Thermo Fisher Scientific, Uppsala, Sweden) were part of routine investigations. The quantification thresholds were 0.10 kUA/L for sIgE and 0.01 mgA/L for sIgG (18, 19). The patient’s pulmonary function test results were retrieved from medical charts.

Data Analysis

Results were expressed as the basophil or lymphocyte stimulation index (SI), which is the ratio between the level of activation with the allergen and the level of activation with reaction buffer, with a threshold of 2 for allergy diagnosis. Statistical analysis was performed with the R statistical software (20). For BAT, optimal cutoff points were determined with the “OptimalCutpoints” package (21). The Youden index, which defines the maximum potential effectiveness of a biomarker to classify a disease status at a specific cutoff, was also calculated (22). Intertest correlation was estimated using Pearson’s correlation coefficient. Mean SI of each group were compared via Wilcoxon’s or Kruskal-Wallis tests as appropriate. A two-sided p-value < 0.05 was considered statistically significant.

Ethics Statement

All the experimental protocols were approved by the institutional ethics committee and GDPR commission with the reference number 2019–270. All methods used were carried out in accordance with relevant national guidelines. Written informed consent for participation was obtained for this study in accordance with the national legislation and the institutional requirements (23, 24).

RESULTS

Demography

The cohort was comprised of 20 CF patients, 25 asthmatic patients, 4 COPD patients and 18 patients with other chronic pulmonary diseases (6 pulmonary arterial hypertension, 4 idiopathic pulmonary fibrosis, 3 emphysema, 2 chronic bronchiectasis, 1 lymphangioleiomyomatosis, 1 idiopathic
FIGURE 1 | BAT protocol. For each patient in the study, we sampled 1 EDTA tube for BAT. The whole blood was mixed with staining antibodies, stimulation buffer and allergen or controls. After incubation at 37°C, red cell lysis and wash, cells were analyzed on FACS.

TABLE 1 | Demographic and laboratory data of the study cohort.

|                         | ABPA       | AF-S       | Control    | Total      | p    |
|-------------------------|------------|------------|------------|------------|------|
| n                       | 6          | 25         | 36         | 67         |      |
| Age (years)             | 37.5       | 49.5       | 57.0       | 53.0       | 0.025|
|                         | (16.3–61.8)| (25.0–75.0)| (26.7–78.0)| (24.3–76.4)|      |
| Male/Female             | 3/3        | 9/16       | 14/22      | 27/40      | 0.797|
| Cystic fibrosis         | 4          | 10         | 7          | 20         | 0.020|
| Asthma                  | 1          | 8          | 15         | 25         | 0.514|
| COPD                    | 1          | 2          | 2          | 4          | 0.509|
| Others                  | 0          | 5          | 12         | 18         | 0.097|
| Lung transplantation    | 2/6        | 6/25       | 14/36      | 22/67      | 0.454|
|                         | (8.2–9.1)  | (0.6–23.6) | (0.1–13.2) | (0.1–19.7) |      |
| Time since transplantation (years) | 8.6 | 7.7 | 1.7 | 4.5 | 0.294 |
|                         | (198.7–6,685.8) | (16.6–1,139.0) | (2.0–266.3) | (3.0–1,413.5) | <10⁻³ |
| Bacterial colonization  | 3/6        | 9/25       | 5/36       | 17/67      | 0.019|
| Fungal colonization     | 3/6        | 6/25       | 2/36       | 11/67      | 0.005|
| Total IgE (kIU/L)       | 1,132.0    | 197.0      | 27.5       | 66.7       | <10⁻³|
|                         | (198.7–6,685.8) | (16.6–1,139.0) | (2.0–266.3) | (3.0–1,413.5) |      |
| IgE AF (kUA/L)          | 16.8       | 0.4        | 0.05       | 0.10       | <10⁻³|
|                         | (0.5–66.3) | (0.1–15.8) | (0.01–0.09) | (0.01–19.9) |      |
| IgG AF (mgA/L)          | 46.8       | 18.2       | 12.3       | 16.6       | 0.002|
|                         | (22.0–79.1)| (4.9–52.9) | (3.1–56.6) | (3.4–59.0) |      |
| Eosinophils (/mm³)      | 300        | 100        | 100        | 100        | 0.564|
|                         | (0–800)    | (100–600)  | (0–600)    | (0–700)    |      |

ABPA, allergic bronchopulmonary aspergillosis; AF, Aspergillus fumigatus; AF-S, Aspergillus fumigatus sensitization; COPD, chronic obstructive pulmonary disease.

chronic eosinophilic pneumonia, 1 infectious pneumonitis). The ABPA group was composed of 6 patients, most of them were CF patients (4/6). The AF-S group included 25 patients, especially CF (10) and asthmatic (8) patients. The control group (n = 36) was composed of 7 CF patients, 15 asthmatic patients, 2 COPD and 12 patients with other chronic pulmonary diseases. Demographic data are summarized in Table 1.
BAT With AF Extract Displayed Good Performances for ABPA Diagnosis

BAT dose-response to AF extract showed that 50 ng/mL yielded a maximal response, and was therefore the optimal concentration to be used in further BAT (Supplementary Figure 1). BAT was positive in all ABPA patients (Figure 2). BAT discriminated both ABPA ($p = 0.0028$) and AF-S patients ($p = 0.00023$) from controls. However, BAT could not distinguish between ABPA and AF-S patients ($p = 0.72$). Comparing results in ABPA and the control groups, with the usual SI threshold of 2, BAT with AF extract displayed 100% sensitivity and 65.5% specificity. An optimized SI threshold allowing for the best Youden index was calculated as 6.55. This optimized SI retained 100% sensitivity but specificity increased to 77.6% (Table 2). The area under the curve (AUC) was 0.84 BAT with AF extract and 0.83 for sIgE to AF. Youden index was 0.78 for BAT with the optimized SI cut-off, but only 0.66 for sIgE to AF extract.

BAT With Molecular Components Further Improved BAT Performance

In positive (SI $\geq 2$) BAT with AF extract, a dose-response BAT was performed with each of the five AF molecular components. Six AF-S and 6 ABPA patients were tested (Figure 3). There was no significant difference in BAT AF responses for these patients (Figure 3A). The mean responses with each AF molecular component were higher in ABPA patients, but only BAT with Asp f 4 at 10 ng/mL reached the significance level (basophil SI of 10.56 in ABPA group vs. 1.24 in no ABPA group, $p = 0.0002$) (Figures 3B–E).

Matrix Correlation

As illustrated in Figure 4, total IgE were more strongly correlated with sIgE to AF ($r = 0.53$, $p = 0.01$) than IgG to AF ($r = -0.03$, $p = 0.001$), although sIgE were correlated with sIgG to AF ($r = 0.29$, $p = 0.003$). BAT AF was correlated with sIgG ($r = 0.45$, $p < 10^{-3}$) and IgE ($r = 0.35$, $p = 0.01$) to AF. Tiffeneau index was inversely correlated with the basophil count ($r = -0.36$, $p = 0.03$) and sIgE to AF levels ($r = -0.35$, $p = 0.01$). The FEV1 ( Forced Expiratory Volume in 1 second) was strongly correlated with FVC (Forced Vital Capacity) ($r = 0.62$, $p = <10^{-3}$).

DISCUSSION

Data on BAT as a tool for ABPA diagnosis are scarce, with only five previous studies from our and other teams (12–16). Four of them have focused on CF patients, an underlying disease associated with the highest ABPA incidence (25) and the global conclusion was that BAT could improve ABPA diagnosis in CF patients. The study of Prasad et al. displayed more contrasted results on asthmatic patients. The present study brings further insights, from a clinical viewpoint, into the usefulness of BAT for ABPA diagnosis in asthmatic patients.

First, we demonstrated the absence of a plateau phase in basophil responses to high AF concentrations. This finding suggests that the basophil signaling switch induced by supraoptimal allergen concentrations does occur with AF extract, similarly to experimental conditions of highest response induced by equivalent amounts of allergens and IgE bound.

### Table 2

| Optimized cutoff | AUC (5–95 percentile) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Youden index |
|------------------|-----------------------|-----------------|-----------------|---------|---------|-------------|
| Total IgE        | 90                    | 0.68 (0.54–0.82) | 66.7            | 66.7    | 59.3    | 0.33        |
| IgE AF           | 0.24                  | 0.83 (0.71–0.94) | 75.0            | 90.9    | 85.7    | 0.66        |
| IgG AF           | 27                    | 0.69 (0.53–0.84) | 76.2            | 65.5    | 61.5    | 0.42        |
| BAT with AF extract | 6.55                | 0.84 (0.74–0.94) | 100             | 77.6    | 27.8    | 0.78        |

Optimization consisted in the identification of the cut-off value associated with the best Youden index.

AF, Aspergillus fumigatus; AUC, Area under curve; BAT, Basophil activation test; NPV, Negative predictive value; PPV, Positive predictive value.
to mast cell and basophil FcεRI (26, 27). The bell-shaped curve of AF-induced basophil activation indicates the need for standardized concentrations of AF extract for BAT, and its potential use as a follow-up test through the monitoring of CD-sens and EC-50 (28, 29).

Secondly, we confirmed that BAT with AF extract performs better than humoral markers (total IgE, IgE to AF and IgG to AF) for ABPA diagnosis. With a 100% negative predictive value, BAT could assist with ruling out ABPA in clinical settings.

In order to improve ABPA diagnostic accuracy, we performed BAT with AF molecular components in BAT AF-positive patients from our cohort. The soluble form of ImmunoCAP® antigens was employed. Overall, ABPA patients displayed higher BAT responses to all the molecular components as compared to AF crude extract. Asp f 4 BAT significantly discriminated ABPA from mere AF-sensitization. Serum sIgE to Asp f 4 has been reported as a better discriminant than AF extract and other AF molecular components for ABPA diagnosis in CF patients (9, 30–32). Hence, IgE immunization against Asp f 4 appears as a relevant marker of ABPA pathophysiology. Functions of this protein in Aspergillus sp have not been described yet. Ramachandran et al have studied the structure and immunogenicity of this protein, providing evidence of the key role of C-Terminal cysteine residues for IgE binding (33).

Basophil activation has been correlated with a strong and effective allergic immune activation, lung damage and pulmonary symptoms (34). We speculate that strong BAT responses in ABPA patients are related to their complex molecular sensitization profile (35).

The main limitations of our study were its monocentric design and the relatively small size of the cohort, hence calling for
confirmation through larger studies. The main novelty of this study is the evidence of an improved discrimination between AF-S and ABPA, by using AF molecular components. In conclusion, cellular functional assays are easy to implement in the routine clinical laboratory for direct and personalized evaluation of each patient's functional responses to AF extract and proteins. They might thus be the next first-line test for ABPA diagnosis.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

MM, MG, CG, and JV contributed conception and design of the study. MM, YS, and FM performed the experiments. CC, SR, and MR-G performed the statistical analysis. J-LM wrote the first draft of the manuscript. All authors contributed to manuscript revision and read and approved the submitted version.

**REFERENCES**

1. Greenberger PA, Bush RK, Demain JG, Luong A, Slavin RG, Knutsen AP. Allergic bronchopulmonary aspergillosis. *J Allergy Clin Immunol Pract.* (2014) 2:703–8. doi: 10.1016/j.jaip.2014.08.007

2. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. *Clin Exp Allergy J Br Soc Allergy Clin Immunol.* (2013) 43:850–73. doi: 10.1111/cea.12141

3. Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. *Eur Respir Rev Off J Eur Respir Soc.* (2011) 20:156–74. doi: 10.1183/09059180.00031011

4. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. *Ann Intern Med.* (1977) 86:405–14. doi: 10.7326/0003-4819-86-4-405

5. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis–state of the art: cystic fibrosis foundation consensus conference. *Clin Infect Dis Off Publ Infect Dis Soc Am.* (2003) 37:5225–26. doi: 10.1086/376525

6. Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, et al. Fungi and allergic lower respiratory tract diseases. *J Allergy Clin Immunol.* (2012) 129:280–91; quiz 292–3. doi: 10.1016/j.jaci.2011.12.970

7. Muthu V, Sehgal IS, Dhooria S, Aggarwal AN, Agarwal R. Utility of recombinant Aspergillus fumigatus antigens in the diagnosis of allergic bronchopulmonary aspergillosis: a systematic review and diagnostic test accuracy meta-analysis. *Clin Exp Allergy J Br Soc Allergy Clin Immunol.* (2018) 48:1107–36. doi: 10.1111/cea.13216

8. Muthu V, Singh P, Choudhary H, Sehgal IS, Dhooria S, Prasad KT, et al. Diagnostic cutoffs and clinical utility of recombinant aspergillus fumigatus antigens in the diagnosis of allergic bronchopulmonary aspergillosis. *J Allergy Clin Immunol Pract.* (2019) 11:19. doi: 10.1016/j.jaip.2019.08.041

9. Vitte J, Ranque S, Carpin A, Romain T, Cassagne C, et al. Multivariate analysis as a support for diagnostic flowcharts in allergic bronchopulmonary aspergillosis: a proof-of-concept study. *Front Immunol.* (2017) 8:1019. doi: 10.3389/fimmu.2017.01019

10. Hoffmann HJ, Santos AF, Mayorga C, Nopp A, Eberlein B, Ferrer M, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. *Allergy.* (2015) 70:1393–405. doi: 10.1111/all.12698

11. Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R, Hilger C, Hoffmaier S, et al. EAACI molecular allergology user's guide. *Pediatr Allergy Immunol Off Publ Eur Pediatr Allergy Immunol.* (2016) 27:1–250. doi: 10.1111/pai.2016.27.issue-523

12. Gernez Y, Waters J, Mirković B, Lavelle GM, Dunn CE, Davies ZA, et al. Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis. *Eur Respir J.* (2016) 47:177–85. doi: 10.1183/13993003.01068-2015

13. Mirković B, Lavelle GM, Azim AA, Helma K, Gargoum FS, Mollok Y, et al. The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosis. *J Allergy Clin Immunol.* (2016) 137:436–443.e9. doi: 10.1016/j.jaci.2015.07.045

14. Katelari A, Tzanoudaki M, Noni M, Kanariou M, Theodoridou M, Kanavakis E, et al. The role of basophil activation test in allergic bronchopulmonary aspergillosis and Aspergillus fumigatus sensitization in cystic fibrosis patients. *J Cyst Fibros Off J Eur Cyst Fibros Soc.* (2016) 15:587–96. doi: 10.1016/j.jcf.2016.02.004

15. Michel M, Gomez C, Sereme Y, Gouitaa M, Chartier C, Blanchard P, et al. Evaluation of cellular responses for the diagnosis of allergic bronchopulmonary mycosis: a preliminary study in cystic fibrosis patients. *Front Immunol.* (2020) 10:3149. doi: 10.3389/fimmu.2019.03149

16. Prasad KT, Muthu V, Sehgal IS, Dhooria S, Singh P, Sachdeva MUS, et al. The utility of the basophil activation test in differentiating asthmatic subjects with and without allergic bronchopulmonary aspergillosis. *Mycoses.* (2020) 63:588–95. doi: 10.1111/myc.13081
17. Hemmings O, Kwok M, McKendry R, Santos AF. Basophil activation test: old and new applications in allergy. *Carr Allergy Asthma Rep.* (2018) 18:77. doi: 10.1007/s11882-018-0831-5

18. Agarwal R, Aggarwal AN, Garg M, Saikia B, Chakrabarti A. Cut-off values of serum IgE (total and *A. fumigatus*-specific) and eosinophil count in differentiating allergic bronchopulmonary aspergillosis from asthma. *Mycoses.* (2014) 57:659–63. doi: 10.1111/myc.12214

19. Agarwal R, Dua D, Choudhary H, Aggarwal AN, Sehgal IS, Dhooria S, et al. Role of Aspergillus fumigatus-specific IgG in diagnosis and monitoring treatment response in allergic bronchopulmonary aspergillosis. *Mycoses.* (2017) 60:33–9. doi: 10.1111/myc.12541

20. R Foundation for Statistical Computing. *R: A language and environment for statistical computing.* [Internet]. Vienna, Austria: R Development Core Team (2005). Available online at: http://www.R-project.org

21. López-Ratón M, Rodríguez-Álvarez MX, Cadarso-Suárez C, Gude-Sampedro F. OptimalCutpoints: an R package for selecting optimal cutpoints in diagnostic tests. *J Stat Softw.* (2014) 61:1–36. doi: 10.18637/jss.v061.i08

22. Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF. Youden index and optimal cut-point estimated from observations affected by a lower limit of detection. *Biom J Biom Z.* (2008) 50:419–30. doi: 10.1002/bimj.200710415

23. LOI n° 2012-300 du 5 mars 2012. *Relative aux recherches impliquant la personne humaine.* 2012-30 (2012).

24. Décret n° 2016-1537 du 16 novembre 2016. *relatif aux recherches impliquant la personne humaine.* 2016-1537 Nov 16. (2016).

25. Muldoon EG, Streek ME, Patterson KC. Allergic and noninvasive infectious pulmonary aspergillosis syndromes. *Clin Chest Med.* (2017) 38:521–34. doi: 10.1016/j.ccm.2017.04.012

26. Huber M. Activation/Inhibition of mast cells by supra-optimal antigen concentrations. *Cell Commun Signal CCS.* (2013) 11:7. doi: 10.1186/1478-811X-11-7

27. Heidlerberger M, Kendall FE. A quantitative theory of the precipitin reaction: iii. the reaction between crystalline egg albumin and its homologous antibody. *J Exp Med.* (1935) 62:697–720. doi: 10.1084/jem.62.5.697

28. Santos AF, Douiri A, Bécares N, Wu S-Y, Stephens A, Rudulovic S, et al. Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children. *J Allergy Clin Immunol.* (2014) 134:645–52. doi: 10.1016/j.jaci.2014.04.039

29. Johansson SGO, Lilja G, Hallberg J, Nopp A. A clinical follow-up of omalizumab in routine treatment of allergic asthma monitored by CD-sens. *Immun Inflamm Dis.* (2018) 18:95. doi: 10.1002/id3.225

30. Hemmann S, Nikolaizik VH, Schöni MH, Blaser K, Cramer R. Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy. *Eur J Immunol.* (1998) 28:1155–60.

31. Casaulta C, Fluckiger S, Cramer R, Blaser K, Schoeni MH. Time course of antibody response to recombinant Aspergillus fumigatus antigens in cystic fibrosis with and without ABPA. *Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol.* (2005) 16:217–25. doi: 10.1111/j.1399-3038.2005.00262.x

32. Knutsen AP, Hutcheson PS, Slavin RG, Kurup VP. IgE antibody to Aspergillus fumigatus recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis. *Allergy.* (2004) 59:198–203. doi: 10.1111/j.1398-9995.2003.00310.x

33. Ramachandran H, Banerjee B, Greenberger PA, Kelly KJ, Fink JN, Kurup VP. Role of C-terminal cysteine residues of Aspergillus fumigatus allergen Asp f 4 in immunoglobulin E binding. *Clin Diagn Lab Immunol.* (2004) 11:261–5. doi: 10.1128/CDLI.11.2.261-265.2004

34. Kauffman HF, Tomee JFC. Inflammatory cells and airway defense against aspergillus fumigatus. *Immunol Allergy Clin North Am.* (1998) 18:619–40. doi: 10.1016/S0889-8561(05)70025-4

35. Vitte J, Romain T, Carsin A, Gouitaa M, Stremler-Le Bel N, Baravalle-Einaudi M, et al. Aspergillus fumigatus components distinguish IgE but not IgG4 profiles between fungal sensitization and allergic broncho-pulmonary aspergillosis. *Allergy.* (2016) 71:1640–3. doi: 10.1111/all.13051

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Michel, Sereme, Mankouri, Gouitaa, Gautier, Miège, Cassagne, Ranque, Reynaud-Gaubert and Vitte. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.